10x Genomics, Inc. — Director's Dealing 2021

Jun 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-06-01

Reporting Person: STUELPNAGEL JOHN R (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-01	Class A Common Stock	S	1597	$171.5829	Disposed	411894	Direct
2021-06-01	Class A Common Stock	S	703	$172.5563	Disposed	411191	Direct
2021-06-01	Class A Common Stock	S	600	$173.72	Disposed	410591	Direct
2021-06-01	Class A Common Stock	S	1500	$174.80	Disposed	409091	Direct
2021-06-01	Class A Common Stock	S	2400	$175.7661	Disposed	406691	Direct
2021-06-01	Class A Common Stock	S	100	$176.72	Disposed	406591	Direct
2021-06-01	Class A Common Stock	S	300	$178.2133	Disposed	406291	Direct
2021-06-01	Class A Common Stock	S	300	$179.7767	Disposed	405991	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2: This transaction was executed in multiple trades at prices ranging from $171.04 to $172.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $172.09 to $173.025. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $173.16 to $174.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $174.27 to $175.21. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This transaction was executed in multiple trades at prices ranging from $175.44 to $176.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F7: This transaction was executed in multiple trades at prices ranging from $177.745 to $178.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F8: This transaction was executed in multiple trades at prices ranging from $179.38 to $180.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.